Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
作者信息
Ferrara Felicetto
机构信息
Division of Hematology, Cardarelli Hospital, Naples, Italy.
出版信息
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
Abstract
摘要
相似文献
1
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
2
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.老年急性髓系白血病患者的更多选择：维奈克拉联合小剂量阿糖胞苷。
Chin Clin Oncol. 2019 Oct;8(S1):S25. doi: 10.21037/cco.2019.09.03.
3
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.维奈托克单药治疗以及联合去甲基化药物或低剂量阿糖胞苷用于复发和难治性急性髓系白血病的系统评价和荟萃分析
Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.
4
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.孕期难治性急性髓系白血病采用维奈克拉、大剂量阿糖胞苷和米托蒽醌治疗。
Br J Haematol. 2021 Jan;192(2):e60-e63. doi: 10.1111/bjh.17220. Epub 2020 Nov 21.
5
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
6
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.维奈托克和阿伐麦布均对阿糖胞苷和克拉屈滨耐药的急性髓系白血病细胞具有细胞毒性。
BMC Cancer. 2020 Oct 12;20(1):984. doi: 10.1186/s12885-020-07469-x.
7
Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?低甲基化药物或低剂量阿糖胞苷和维奈托克为何如此有效？
Curr Opin Hematol. 2019 Mar;26(2):71-76. doi: 10.1097/MOH.0000000000000485.
8
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.新型低甲基化剂NTX-301作为单一疗法及与维奈托克联合用于急性髓系白血病的临床前疗效
Blood Cancer J. 2022 Apr 11;12(4):57. doi: 10.1038/s41408-022-00664-y.
9
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).比较维奈托克联合低甲基化药物与低甲基化药物为基础的治疗方案用于初治 TP53 突变急性髓系白血病：来自髓系恶性肿瘤和肿瘤性疾病联盟（COMMAND）的结果。
Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2.
10
Hypomethylating agents with venetoclax: have we discovered the holy grail?联合维奈托克的去甲基化药物：我们是否已经发现了圣杯？
Curr Opin Hematol. 2020 Mar;27(2):76-80. doi: 10.1097/MOH.0000000000000560.
引用本文的文献
1
Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review.急性髓系白血病诊断及微小残留病检测的当前及新兴技术：一篇全面的叙述性综述
Cancers (Basel). 2023 Feb 21;15(5):1362. doi: 10.3390/cancers15051362.
2
High Expression of RhoBTB3 Predicts Favorable Chemothrapy Outcomes in non-M3 Acute Myeloid Leukemia.RhoBTB3高表达预示非M3型急性髓系白血病化疗效果良好。
J Cancer. 2021 May 17;12(14):4229-4239. doi: 10.7150/jca.50472. eCollection 2021.
3
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.评价维奈托克联合阿扎胞苷、地西他滨或低剂量阿糖胞苷治疗急性髓系白血病的疗效。
Expert Rev Hematol. 2021 May;14(5):407-417. doi: 10.1080/17474086.2021.1938533. Epub 2021 Jun 15.
4
Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax.奥巴托克斯可降低急性髓系白血病细胞系的细胞活力，且与它们对维奈托克的敏感性无关。
Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):124-127. doi: 10.1016/j.htct.2021.01.004. Epub 2021 Mar 13.
5
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.维奈托克联合地西他滨与强化化疗治疗急性髓系白血病的疗效比较：基于治疗相关死亡率风险的倾向评分匹配分析。
Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24.
6
Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.靶向急性髓系白血病的细胞代谢及患者异质性的作用。
Cells. 2020 May 7;9(5):1155. doi: 10.3390/cells9051155.
本文引用的文献
1
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.低甲基化药物联合维奈托克治疗急性髓系白血病：临床试验数据更新及实际应用注意事项。
Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13.
Zotero 插件